Huo Lei, Sugimura Jun, Tretiakova Maria S, Patton Kurt T, Gupta Rohit, Popov Boris, Laskin William B, Yeldandi Anjana, Teh Bin Tean, Yang Ximing J
Department of Pathology, Northwestern Memorial Hospital, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.
Hum Pathol. 2005 Mar;36(3):262-8. doi: 10.1016/j.humpath.2005.01.011.
C- kit encodes the membrane-bound tyrosine kinase KIT, whose expression has been identified in several types of human neoplasms. Recently, KIT has been reported to be a marker for chromophobe renal cell carcinoma (RCC) and renal angiomyolipoma. However, expression of this molecule has not been adequately studied in other renal tumors, particularly oncocytoma, which may morphologically resemble chromophobe RCC. In this study, we analyzed c- kit messenger RNA (mRNA) levels in 17 chromophobe RCCs and 20 renal oncocytomas obtained from complementary DNA (cDNA) microarrays. Furthermore, comprehensive immunohistochemical analysis of KIT protein using a monoclonal antibody was performed in 226 renal tumors including chromophobe RCC (n=40), oncocytoma (n=41), clear-cell RCC (n=40), renal angiomyolipoma (n=29), and papillary RCC (n=21) on tissue microarrays (TMAs) and was compared with immunostaining results from 25 chromophobe RCCs and 30 oncocytomas using standard sections. The staining intensity was semiquantitatively graded on a 3-tier scoring system. All chromophobe RCCs and oncocytomas showed significant overexpression of c- kit mRNA. The average increase of mRNA compared with normal kidney tissue was 7.4-fold for chromophobe RCCs and 7.4-fold for oncocytomas. Immunohistochemical expression of KIT was found in most chromophobe RCCs (95% in TMAs and 96% in conventional sections) and oncocytomas (88% in TMAs and 100% in conventional sections) but was infrequently observed in renal angiomyolipomas (17%), papillary RCCs (5%), and clear-cell RCCs (3%). Furthermore, the average KIT immunoreactivity in TMAs was stronger in chromophobe RCC (1.93) and oncocytoma (2.07) than in other subtypes of renal tumors tested, including angiomyolipomas (0.17), papillary RCCs (0.05), and clear-cell RCCs (0.03). In conclusion, we found a significant elevation of c- kit mRNA by cDNA expression microarrays and overexpression of KIT protein by immunohistochemistry not only in chromophobe RCCs but also in oncocytomas. In contrast, immunohistochemical expression of KIT was not detected in most other types of renal cell tumors evaluated. The differential expression of c- kit in these renal tumors may have diagnostic and therapeutic implications.
C-kit编码膜结合酪氨酸激酶KIT,其表达已在几种人类肿瘤中得到鉴定。最近,KIT被报道为嫌色性肾细胞癌(RCC)和肾血管平滑肌脂肪瘤的标志物。然而,该分子在其他肾肿瘤中的表达尚未得到充分研究,尤其是嗜酸细胞瘤,其在形态上可能与嫌色性RCC相似。在本研究中,我们分析了从互补DNA(cDNA)微阵列获得的17例嫌色性RCC和20例肾嗜酸细胞瘤中c-kit信使核糖核酸(mRNA)水平。此外,使用单克隆抗体对KIT蛋白进行了全面的免疫组织化学分析,该分析在组织微阵列(TMA)上对226例肾肿瘤进行,包括嫌色性RCC(n = 40)、嗜酸细胞瘤(n = 41)、透明细胞RCC(n = 40)、肾血管平滑肌脂肪瘤(n = 29)和乳头状RCC(n = 21),并与使用标准切片的25例嫌色性RCC和30例嗜酸细胞瘤的免疫染色结果进行比较。染色强度根据三级评分系统进行半定量分级。所有嫌色性RCC和嗜酸细胞瘤均显示c-kit mRNA显著过表达。与正常肾组织相比,嫌色性RCC的mRNA平均增加7.4倍,嗜酸细胞瘤的mRNA平均增加7.4倍。在大多数嫌色性RCC(TMA中为95%,传统切片中为96%)和嗜酸细胞瘤(TMA中为88%,传统切片中为100%)中发现了KIT的免疫组织化学表达,但在肾血管平滑肌脂肪瘤(17%)、乳头状RCC(5%)和透明细胞RCC(3%)中很少观察到。此外,TMA中KIT的平均免疫反应性在嫌色性RCC(1.93)和嗜酸细胞瘤(2.07)中比在其他测试的肾肿瘤亚型中更强,包括血管平滑肌脂肪瘤(0.17)、乳头状RCC(0.05)和透明细胞RCC(0.03)。总之,我们发现通过cDNA表达微阵列c-kit mRNA显著升高,通过免疫组织化学发现KIT蛋白不仅在嫌色性RCC中而且在嗜酸细胞瘤中过表达。相比之下,在大多数评估的其他类型肾细胞肿瘤中未检测到KIT的免疫组织化学表达。c-kit在这些肾肿瘤中的差异表达可能具有诊断和治疗意义。